Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
46 hedge funds and large institutions have $14.5M invested in Repros Therapeutics Inc. in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 5 closing their positions.
923% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $150K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
53% more capital invested
Capital invested by funds: $9.45M → $14.5M (+$5.05M)
7% more funds holding
Funds holding: 43 → 46 (+3)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.71M |
| 2 |
GAI
General American Investors
New York
|
+$623K |
| 3 |
Renaissance Technologies
New York
|
+$208K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$51.4K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$37.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$111K |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$104K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$92.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$89.1K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$55K |
RPRX Hedge Fund Activity: Q3 2016 in Review
46 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q3 2016, worth a combined $14.5M — up 53% from $9.45M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RPRX positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.71M. The largest seller was Alambic Investment Management, exiting entirely with an estimated $111K sold.
- 46 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q3 2016, up from 43 in Q2 2016.
- Funds reported $14.5M of Repros Therapeutics Inc. stock for Q3 2016, up 53% quarter-over-quarter.
- 8 funds opened new Repros Therapeutics Inc. positions in Q3 2016 and 5 closed out, a net change of +3 holders.
- The largest Repros Therapeutics Inc. buyer in Q3 2016 was Sphera Funds Management, an estimated $1.71M added.
- The largest Repros Therapeutics Inc. seller in Q3 2016 was Alambic Investment Management, an estimated $111K sold.
Based on aggregated 13F filings for Q3 2016.